Company profile
XORTX Therapeutics Inc.
NASDAQ: XRTX · Healthcare · Biotechnology
Canadian filerHQ Vancouver, BCCIK 0001729214Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 16
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ workforce scale, filing timeliness
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.3M
Employees
2
as of 2026-09-25
Market cap
$479.0k
as of 2026-09-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$1.3M-1.7M CAD2021
Total assets$17.4M22.0M CAD2021
Liabilities$4.2M5.3M CAD2021
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is XORTX Therapeutics Inc.’s financial profile?
XORTX Therapeutics Inc. earned -$1.3M in FY2021 net income.
Peers · Healthcare
Nascent Pharma Holdings, Inc.——Halberd Corporation——CERo Therapeutics Holdings, Inc.——Solanbridge Group, Inc.——CaliPharms, Inc.——Canopus Biopharma, Inc.——Key facts
CEOAllen Warren Davidoff
SectorHealthcare
IndustryBiotechnology
HeadquartersVancouver, BC
ExchangeNASDAQ: XRTX
Employees2
IPO date2021-09-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.